This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Literatur
Abelson JL, Curtis GC (1996) Hypothalamic-pituitary-adrenal axis activity in panic disorder — 24-hour secretion of corticotropin and cortisol. Arch Gen Psychiatry 53: 323–331
Abelson JL, Nesse RM (1994) Pentagastrin infusions in patients with panic disorder. I. Symptoms and cardiovascular responses. Biol Psychiatry 36: 73–83
Abelson JL, Glitz D, Cameron OG, Lee MA, Bronzo M, Curtis GC (1991) Blunted growth hormone response to clonidine in patients with generalized anxiety disorder. Arch Gen Psychiatry 48: 157–162
Abelson JL, Glitz D, Cameron OG, Lee MA, Bronzo M, Curtis GC (1992) Endocrine, cardiovascular, and behavioral responses to clonidine in patients with panic disorder. Biol Psychiatry 32: 18–25
Adams JB, Pyke RE, Costa J et al (1995) A double-blind, placebo-controlled study of a CCK-B receptor antagonist, CI-988, in patients with generalized anxiety disorder. J Clin Psychopharmacol 15: 428–434
Albus M, Zahn TP, Breier A (1992) Anxiogenic properties of yohimbine. I. Behavioral, physiological and biochemical measures. Eur Arch Psychiatry Clin Neurosci 241: 337–344
Aloisi AM, Bianchi M, Lupo C, Sacerdote P, Farabollini F (1999) Neuroendocrine and behavioral effects of CRH blockade and stress in male rats. Physiol Behav 66: 523–528
Alpers GW, Abelson JL, Wilhelm FH, Roth WT (2003) Salivary cortisol response during exposure treatment in driving phobics. Psychosom Med 65: 679–687
Amaral DG (2002) The primate amygdala and the neurobiology of social behavior: implications for understanding social anxiety. Biol Psychiatry 51: 11–17
Andrews G, Stewart G, Allen R, Henderson AS (1990) The genetics of six neurotic disorders: a twin study. J Affect Disord 19: 23–29
Appleby I, Klein D, Sachar E, Levitt M (1981) Biochemical indices of lactate-induced panic: a preliminary report. Raven Press, New York
Argyropoulos SV, Bailey JE, Hood SD et al (2002) Inhalation of 35% CO(2) results in activation of the HPA axis in healthy volunteers. Psychoneuroendocrinology 27: 715–729
Arnsten AF (1998) The biology of being frazzled. Science 280: 1711–1712
Ashton H (1994) Guidelines for the rational use of benzodiazepines. When and what to use. Drugs 48: 25–40
Aston-Jones G, Akaoka H, Charlety P, Chouvet G (1991) Serotonin selectively attenuates glutamate-evoked activation of noradrenergic locus coeruleus neurons. J Neurosci 11: 760–769
Avery DH, Osgood TB, Ishiki DM, Wilson LG, Kenny M, Dunner DL (1985) The DST in psychiatric outpatients with generalized anxiety disorder, panic disorder, or primary affective disorder. Am J Psychiatry 142: 844–848
Ball S, Shekhar A (1997) Basilar artery response to hyperventilation in panic disorder. Am J Psychiatry 154: 1603–1604
Bandelow B (2001) Panik und Agoraphobie — Ursachen, Diagnose und Behandlung. Springer, Wien
Bandelow B (2003) Angst-und Panikerkrankungen. UNI-MED, Bremen
Bandelow B, Sengos G, Wedekind D et al (1997) Urinary excretion of cortisol, norepinephrine, testosterone, and melatonin in panic disorder. Pharmacopsychiatry 30: 113–117 (published erratum p 278)
Bandelow B, Wedekind D, Pauls J, Broocks A, Hajak G, Rüther E (2000a) Salivary cortisol in panic attacks. Am J Psychiatry 157: 454–456
Bandelow B, Wedekind D, Sandvoss V et al (2000b) Diurnal variation of cortisol in panic disorder. Psychiatry Res 95: 245–250
Bandelow B, Späth C, Álvarez Tichauer G, Broocks A, Hajak G, Rüther E (2002a) Early traumatic life events, parental attitudes, family history, and birth risk factors in patients with panic disorder. Compr Psychiatry 43: 269–278
Bandelow B, Zohar J, Hollander E, Kasper S, Möller HJ (2002b) World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders. World J Biol Psychiatry 3: 171–199
Bandelow, Charimo Torrente A, Broocks A, Hajak G, Rüther E (2004) Early traumatic life events, parental rearing styles, family history of mental disorders, and birth risk factors in patients with social anxiety disorder. Eur Arch Psychiatry Clin Neurosci 254(6): 397–405
Bayle FJ, Millet B, Andre C (1999) Biologie des phobies sociales. L’encéphale 25: 345–352
Bell C, Forshall S, Adrover M et al (2002) Does 5-HT restrain panic? A tryptophan depletion study in panic disorder patients recovered on paroxetine. J Psychopharmacol 16: 5–14
Bellodi L, Perna G, Caldirola D, Arancio C, Bertani A, Di Bella D (1998) CO2-induced panic attacks: a twin study. Am J Psychiatry 155: 1184–1188
Benjamin J, Levine J, Fux M, Aviv A, Levy D, Belmaker RH (1995) Doubleblind, placebo-controlled, crossover trial of inositol treatment for panic disorder. Am J Psychiatry 152: 1084–1086
Benkelfat C, Bradwejn J, Meyer E, Ellenbogen M, Milot S, Gjedde A, Evans A (1995) Functional neuroanatomy of CCK4-induced anxiety in normal healthy volunteers. Am J Psychiatry 152: 1180–1184
Benshop RJ, Jacobs R, Sommer B, Schürmeyer TH, Schmidt RE, Schedlowski M (1996) Propranolol and alprazolam differentially affect immunological changes induced by acute emotional stress. FASEB J 10: 517–524
Bhattacharya SK, Chakrabarti A, Sandler M, Glover V (1996) Anxiolytic activity of intraventricularly administered atrial natriuretic peptide in the rat. Neuropsychopharmacology 15: 199–206
Birbaumer N, Grodd W, Diedrich O et al (1998) fMRI reveals amygdala activation to human faces in social phobics. Neuroreport 9: 1223–1226
Bisaga A, Katz JL, Antonini A, Wright CE, Margouleff C, Gorman JM, Eidelberg D (1998) Cerebral glucose metabolism in women with panic disorder. Am J Psychiatry 155: 1178–1183
Boshuisen ML, Ter Horst GJ, Paans AM, Reinders AA, den Boer JA (2002) rCBF differences between panic disorder patients and control subjects during anticipatory anxiety and rest. Biol Psychiatry 52: 126–135
Boulenger J, Patel J, Marangos P (1982) Effects of caffeine and theophylline on adenosine and benzodiazepine receptors in human brain. Neurosci Lett 30: 161–166
Boulenger JP, Uhde TW, Wolff EA, Post RM (1984) Increased sensitivity to caffeine in patients with panic disorders. Preliminary evidence. Arch Gen Psychiatry 41: 1067–1071
Boulenger JP, Jerabek I, Jolicoeur FB, Lavallee YJ, Leduc R, Cadieux A (1996) Elevated plasma levels of neuropeptide Y in patients with panic disorder. Am J Psychiatry 153: 114–116
Bradwejn J, de Montigny C (1984) Benzodiazepines antagonize cholecystokinin-induced activation of rat hippocampal neurones. Nature 312: 363–364
Bradwejn J, Koszycki D (1994) Imipramine antagonism of the panicogenic effects of cholecystokinin tetrapeptide in panic disorder patients. Am J Psychiatry 151: 261–263
Bradwejn J, Koszycki D, Shriqui C (1991) Enhanced sensitivity to cholecystokinin tetrapeptide in panic disorder. Clinical and behavioral findings. Arch Gen Psychiatry 48: 603–610
Bradwejn J, Koszycki D, Couetoux du Tertre A, van Megen H, den Boer J, Westenberg H (1994) The panicogenic effects of cholecystokinin-tetrapeptide are antagonized by L-365,260, a central cholecystokinin receptor antagonist, in patients with panic disorder. Arch Gen Psychiatry 51: 486–493
Bradwejn J, Koszycki D, Paradis M, Reece P, Hinton J, Sedman A (1995) Effect of CI-988 on cholecystokinin tetrapeptide-induced panic symptoms in healthy volunteers. Biol Psychiatry 38: 742–746
Brady LS, Gold PW, Herkenham M, Lynn AB, Whitfield HJ Jr. (1992) The antidepressants fluoxetine, idazoxan and phenelzine alter corticotropin-releasing hormone and tyrosine hydroxylase mRNA levels in rat brain: therapeutic implications. Brain Res 572: 117–125
Brambilla F, Maggioni M (1998) Blood levels of cytokines in elderly patients with major depressive disorder. Acta Psychiatr Scand 97: 309–313
Brambilla F, Bellodi L, Perna G et al (1992) Psychoimmunoendocrine aspects of panic disorder. Neuropsychobiology 26: 12–22
Brambilla F, Bellodi L, Perna G, Garberi A, Panerai A, Sacerdote P (1993) Lymphocyte cholecystokinin concentrations in panic disorder. Am J Psychiatry 150: 1111–1113
Brambilla P, Barale F, Caverzasi E, Soares JC (2002) Anatomical MRI findings in mood and anxiety disorders. Epidemiol Psichiatr Soc 11: 88–99
Brandt CA, Meller J, Keweloh L, Hoschel K, Staedt J, Munz D, Stoppe G (1998) Increased benzodiazepine receptor density in the prefrontal cortex in patients with panic disorder. J Neural Transm 105: 1325–1333
Braune S, Albus M, Frohler M, Hohn T, Scheibe G (1994) Psychophysiological and biochemical changes in patients with panic attacks in a defined situational arousal. Eur Arch Psychiatry Clin Neurosci 244: 86–92
Brawman-Mintzer O, Lydiard RB (1997) Biological basis of generalized anxiety disorder. J Clin Psychiatry 58: 16–26
Breier A, Charney DS, Heninger GR (1986) Agoraphobia with panic attacks. Development, diagnostic stability, and course of illness. Arch Gen Psychiatry 43: 1029–1036
Bremner JD, Krystal JH, Southwick SM, Charney DS (1996a) Noradrenergic mechanisms in stress and anxiety: I. Preclinical studies. Synapse 23: 28–38
Bremner JD, Krystal JH, Southwick SM, Charney DS (1996b) Noradrenergic mechanisms in stress and anxiety: II. Clinical studies. Synapse 23: 39–51
Britton KT, Akwa Y, Spina MG, Koob GF (2000) Neuropeptide Y blocks anxiogenic-like behavioral action of corticotropin-releasing factor in an operant conflict test and elevated plus maze. Peptides 21: 37–44
Broocks A, Bandelow B, George A et al (2000) Increased psychological responses and divergent neuroendocrine responses to m-CPP and ipsapirone in patients with panic disorder. Int Clin Psychopharmacol 15: 153–161
Buchsbaum MS, Wu JC, DeLisi LE, Holcomb HH, Hazlett E, Cooper-Langston K, Kessler R (1987) Positron emission tomography studies of basal ganglia and somatosensory cortex neuroleptic drug effects: differences between normal controls and schizophrenic patients. Biol Psychiatry 22: 479–494
Butler J, O’Halloran A, Leonard BE (1992) The Galway Study of Panic Disorder. II: Changes in some peripheral markers of noradrenergic and serotonergic function in DSM III-R panic disorder. J Affect Disord 26: 89–99
Caldirola D, Perna G, Arancio C, Bertani A, Bellodi L (1997) The 35% CO2 challenge test in patients with social phobia. Psychiatry Res 71: 41–48
Cameron OG, Nesse RM (1988) Systemic hormonal and physiological abnormalities in anxiety disorders. Psychoneuroendocrinology 13: 287–307
Cameron OG, Smith CB, Lee MA, Hollingsworth PJ, Hill EM, Curtis GC (1990) Adrenergic status in anxiety disorders: platelet alpha2-adrenergic receptor binding, blood pressure, pulse, and plasma catecholamines in panic and generalized anxiety disorder patients and in normal subjects. Biol Psychiatry 28: 3–20
Carr DB, Sheehan DV, Surman OS et al (1986) Neuroendocrine correlates of lactate-induced anxiety and their response to chronic alprazolam therapy. Am J Psychiatry 143: 483–494
Carter MM, Hollon SD, Carson R, Shelton RC (1995) Effects of a safe person on induced distress following a biological challenge in panic disorder with agoraphobia. J Abnorm Psychol 104: 156–163
Cavallini MC, Perna G, Caldirola D, Bellodi L (1999) A segregation study of panic disorder in families of panic patients responsive to the 35% CO2 challenge. Biol Psychiatry 46: 815–820
Charney D, Bremner D (1999) The neurobiology of anxiety disorders. In: Charney D (ed). Neurobiology of mental illness. Oxford University Press, Oxford, pp 494–517
Charney DS, Deutch A (1996) A functional neuroanatomy of anxiety and fear: implications for the pathophysiology and treatment of anxiety disorders. Crit Rev Neurobiol 10: 419–446
Charney DS, Heninger GR (1985) Noradrenergic function and the mechanism of action of antianxiety treatment. I. The effect of longterm alprazolam treatment. Arch Gen Psychiatry 42: 458–467
Charney DS, Heninger GR (1986) Abnormal regulation of noradrenergic function in panic disorders. Effects of clonidine in healthy subjects and patients with agoraphobia and panic disorder. Arch Gen Psychiatry 43: 1042–1054
Charney DS, Heninger GR, Breier A (1984) Noradrenergic function in panic anxiety. Effects of yohimbine in healthy subjects and patients with agoraphobia and panic disorder. Arch Gen Psychiatry 41: 751–763
Charney DS, Heninger GR, Jatlow PI (1985) Increased anxiogenic effects of caffeine in panic disorders. Arch Gen Psychiatry 42: 233–243
Charney DS, Woods SW, Goodman WK et al (1986) Drug treatment of panic disorder: the comparative efficacy of imipramine, alprazolam, and trazodone. J Clin Psychiatry 47: 580–586
Charney DS, Woods SW, Goodman WK, Heninger GR (1987a) Neurobiological mechanisms of panic anxiety: biochemical and behavioral correlates of yohimbine-induced panic attacks. Am J Psychiatry 144: 1030–1036
Charney DS, Woods SW, Goodman WK, Heninger GR (1987b) Serotonin function in anxiety. II. Effects of the serotonin agonist MCPP in panic disorder patients and healthy subjects. Psychopharmacology 92: 14–24
Charney DS, Woods SW, Heninger GR (1989) Noradrenergic function in generalized anxiety disorder: effects of yohimbine in healthy subjects and patients with generalized anxiety disorder. Psychiatry Res 27: 173–182
Charney DS, Woods SW, Krystal JH, Nagy LM, Heninger GR (1992) Noradrenergic neuronal dysregulation in panic disorder: the effects of intravenous yohimbine and clonidine in panic disorder patients. Acta Psychiatr Scand 86: 273–282
Chatterjee S, Sunitha TA, Velayudhan A, Khanna S (1997) An investigation into the psychobiology of social phobia: personality domains and serotonergic function. Acta Psychiatr Scand 95: 544–550
Condren RM, O’Neill A, Ryan MC, Barrett P, Thakore JH (2002) HPA axis response to a psychological stressor in generalised social phobia. Psychoneuroendocrinology 27: 693–703
Coplan JD, Lydiard RB (1998) Brain circuits in panic disorder. Biol Psychiatry 44: 1264–1276
Coplan JD, Liebowitz MR, Gorman JM et al (1992a) Noradrenergic function in panic disorder. Effects of intravenous clonidine pretreatment on lactate induced panic. Biol Psychiatry 31: 135–146
Coplan JD, Sharma T, Rosenblum LA, Friedman S, Bassoff TB, Barbour RL, Gorman JM (1992b) Effects of sodium lactate infusion on cisternal lactate and carbon dioxide levels in nonhuman primates. Am J Psychiatry 149: 1369–1373
Coplan JD, Pine D, Papp LA, Martinez J, Klein DF, Gorman JM (1994) CO2-induced panic and lack of cortisol response. In: American Psychiatric Association (ed) New Research Abstracts. American Psychiatric Association, Philadelphia
Coplan JD, Papp LA, Martinez J et al (1995a) Persistence of blunted human growth hormone response to clonidine in fluoxetine-treated patients with panic disorder. Am J Psychiatry 152: 619–622
Coplan JD, Pine D, Papp L, Martinez J, Cooper T, Rosenblum LA, Gorman JM (1995b) Uncoupling of the noradrenergic-hypothalamic-pituitary-adrenal axis in panic disorder patients. Neuropsychopharmacology 13: 65–73
Coplan JD, Papp LA, Pine D et al (1997) Clinical improvement with fluoxetine therapy and noradrenergic function in patients with panic disorder. Arch Gen Psychiatry 54: 643–648
Cornelius RR, Averill JR (1983) Sex differences in fear of spiders. J Pers Soc Psychol 45: 377–383
Coryell W, Noyes R, Schlechte J (1989) The significance of HPA axis disturbance in panic disorder. Biol Psychiatry 25: 989–1002
Coupland NJ (2001) Social phobia: etiology, neurobiology, and treatment. J Clin Psychiatry 62: 25–35
Coupland NY, Bailey JE, Potokar JP (1995) Abnormal cardioascular responses to standing in panic disorder and social phobia. J Psychopharmacol 9: A73
Cowley DS, Dager SR, McClellan J, Roy-Byrne PP, Dunner DL (1988) Response to lactate infusion in generalized anxiety disorder. Biol Psychiatry 24: 409–414
Cowley DS, Dager SR, Roy Byrne PP, Avery DH, Dunner DL (1991) Lactate vulnerability after alprazolam versus placebo treatment of panic disorder. Biol Psychiatry 30: 49–56
Curtis G, Buxton M, Lippman D, Nesse R, Wright J (1976) »Flooding in vivo« during the circadian phase of minimal cortisol secretion: anxiety and therapeutic success without adrenal cortical activation. Biol Psychiatry 11: 101–107
Curtis AL, Lechner SM, Pavcovich LA, Valentino RJ (1997) Activation of the locus coeruleus noradrenergic system by intracoerulear microinfusion of corticotropin-releasing factor: effects on discharge rate, cortical norepinephrine levels and cortical electroencephalographic activity. J Pharmacol Exp Ther 281: 163–172
Daenen EW, Wolterink G, Gerrits MA, Van Ree JM (2002) Amygdala or ventral hippocampal lesions at two early stages of life differentially affect open field behaviour later in life; an animal model of neurodevelopmental psychopathological disorders. Behav Brain Res 131: 67–78
Dager SR, Swann AC (1996) Advances in brain metabolism research: toward a moving picture of neural activity. Biol Psychiatry 39: 231–233
Dager SR, Rainey JM, Kenny MA, Artru AA, Metzger GD, Bowden DM (1990) Central nervous system effects of lactate infusion in primates. Biol Psychiatry 27: 193–204
Dager SR, Friedman SD, Heide A et al (1999) Two-dimensional proton echo-planar spectroscopic imaging of brain metabolic changes during lactate-induced panic. Arch Gen Psychiatry 56: 70–77
Dajas F, Nin A, Barbeito L (1986) Urinary norepinephrine excretion in panic and phobic disorders. J Neural Transm 65: 75–81
Daniels D, Plomin R (1985) Origins of individual differences in infant shyness. Devel Psychol 21: 118–121
Dantendorfer K, Prayer D, Kramer J et al (1996) High frequency of EEG and MRI brain abnormalities in panic disorder. Psychiatry Res 68: 41–53
Dantzer R (2001) Cytokine-induced sickness behavior: mechanisms and implications. Ann NY Acad Sci 933: 222–234
Dautzenberg FM, Hauger RL (2002) The CRF peptide family and their receptors: yet more partners discovered. Trends Pharmacol Sci 23: 71–77
Davidson JR, Krishnan KR, Charles HC, Boyko O, Potts NL, Ford SM, Patterson L (1993) Magnetic resonance spectroscopy in social phobia: preliminary findings. J Clin Psychiatry 54: 19–25
Davidson RJ, Marshall JR, Tomarken AJ, Henriques JB (2000) While a phobic waits: regional brain electrical and autonomic activity in social phobics during anticipation of public speaking. Biol Psychiatry 47: 85–95
Davis M (1997) Neurobiology of fear responses: the role of the amygdala. J Neuropsychiatr Clin Neurosci 9: 382–402
De Bellis MD, Keshavan MS, Shifflett H et al (2002) Superiortemporal gyrus volumes in pediatric generalized anxiety disorder. Biol Psychiatry 51: 553–562
De Cristofaro MT, Sessarego A, Pupi A, Biondi F, Faravelli C (1993) Brain perfusion abnormalities in drug-naive, lactate-sensitive panic patients: a SPECT study. Biol Psychiatry 33: 505–512
De Oca BM, DeCola JP, Maren S, Fanselow MS (1998) Distinct regions of the periaqueductal gray are involved in the acquisition and expression of defensive responses. J Neurosci 18: 3426–3432
Deakin JWF, Graeff FG (1991) 5-HT and mechanisms of defence. J Psychopharmacol 5: 305–315
Deckert J, Catalano M, Heils A et al (1997) Functional promoter polymorphism of the human serotonin transporter: lack of association with panic disorder. Psychiatr Genet 7: 45–47
Deckert J, Nothen MM, Franke P et al (1998) Systematic mutation screening and association study of the A1 and A2a adenosine receptor genes in panic disorder suggest a contribution of the A2a gene to the development of disease. Mol Psychiatry 3: 81–85
Deckert J, Catalano M, Syagailo YV et al (1999) Excess of high activity monoamine oxidase A gene promoter alleles in female patients with panic disorder. Hum Mol Genet 8: 621–624
den Boer JA, Westenberg HG (1988) Effect of a serotonin and noradrenaline uptake inhibitor in panic disorder; a double-blind comparative study with fluvoxamine and maprotiline. Int Clin Psychopharmacol 3: 59–74
den Boer JA, Westenberg HG (1990) Serotonin function in panic disorder: a double blind placebo controlled study with fluvoxamine and ritanserin. Psychopharmacology 102: 85–94
Deutch AY, Young CD (1995) A model of the stress-induced activation of prefrontal cortical dopamine systems: coping and the development of prost-traumatic stress disorder. In: Friedman MJ, Charney DS, Deutch AY (eds) Neurobiological and clinical consequences of stress. Lippincott-Raven, Philadelphia, pp 163–175
Devinsky O, Sato S, Theodore WH, Porter RJ (1989) Fear episodes due to limbic seizures with normal ictal scalp EEG: a subdural electrographic study. J Clin Psychiatry 50: 28–30
DiNardo PA, Guzy LT, Jenkins JA, Bak RM, Tomasi SF, Copland M (1988) Etiology and maintenance of dog fears. Behav Res Ther 26: 241–244
Dodd J, Kelly JS (1979) Excitation of CA1 pyramidal neurones of the hippocampus by the tetra-and octapeptide C-terminal fragments of cholecystokinin. J Physiol 295: 61P–62P
Dorow R, Horowski R, Paschelke G, Amin M (1983) Severe anxiety induced by FG 7142, a beta-carboline ligand for benzodiazepine receptors. Lancet 2: 98–99
Eren I, Tukel R, Polat A, Karaman R, Unal S (2003) Evaluation of regional cerebral blood flow changes in panic disorder with Tc99m-HMPAO SPECT. Psychiatry Res 123: 135–143
Eriksson E, Westberg P, Alling C, Thuresson K, Modigh K (1991) Cerebrospinal fluid levels of monoamine metabolites in panic disorder. Psychiatry Res 36: 243–251
Ferrarese C, Appollonio I, Frigo M, Perego M, Piolti R, Trabucchi M, Frattola L (1990) Decreased density of benzodiazepine receptors in lymphocytes of anxious patients: reversal after chronic diazepam treatment. Acta Psychiatr Scand 82: 169–173
Finn CT, Smoller JW (2001) The genetics of panic disorder. Curr Psychiatry Rep 3: 13–137
Fish DR, Gloor P, Quesney FL, Olivier A (1993) Clinical responses to electrical brain stimulation of the temporal and frontal lobes in patients with epilepsy. Pathophysiological implications. Brain 116: 397–414
Fontaine R, Breton G, Dery R, Fontaine S, Elie R (1990) Temporal lobe abnormalities in panic disorder: an MRI study. Biol Psychiatry 27: 304–310
Fossey MD, Lydiard RB, Ballenger JC, Laraia MT, Bissette G, Nemeroff CB (1996) Cerebrospinal fluid corticotropin-releasing factor concentrations in patients with anxiety disorders and normal comparison subjects. Biol Psychiatry 39: 703–707
Fredrikson M, Furmark T (2004) Brain imaging studies in social anxiety disorder. In: Bandelow B, Stein DJ (eds). Social anxiety disorder. Marcel Dekker, New York
Fredrikson M, Wik G, Fischer H, Andersson J (1995) Affective and attentive neural networks in humans: a PET study of Pavlovian conditioning. Neuroreport 7: 97–101
Fredrikson M, Annas P, Fischer H, Wik G (1996) Gender and age differences in the prevalence of specific fears and phobias. Behav Res Ther 34: 33–39
Furmark T, Fischer H, Wik G, Larsson M, Fredrikson M (1997) The amygdala and individual differences in human fear conditioning. Neuroreport 8: 3957–3960
Furmark T, Tillfors M, Marteinsdottir I, Fischer H, Pissiota A, Langstrom B, Fredrikson M (2002) Common changes in cerebral blood flow in patients with social phobia treated with citalopram or cognitivebehavioral therapy. Arch Gen Psychiatry 59: 425–433
Fyer AJ, Mannuzza S, Gallops MS et al (1990) Familial transmission of simple phobias and fears. A preliminary report. Arch Gen Psychiatry 47: 252–256
Fyer AJ, Mannuzza S, Chapman TF, Liebowitz MR, Klein DF (1993) A direct interview family study of social phobia. Arch Gen Psychiatry 50: 286–293
Fyer AJ, Mannuzza S, Chapman TF, Martin LY, Klein DF (1995) Specificity in familial aggregation of phobic disorders. Arch Gen Psychiatry 52: 564–573
Garvey MJ, Crowe RR, Wang Z (1998) An association of NAG levels and a mutation of the CCK gene in panic disorder patients. Psychiatry Res 80: 149–153
Gelernter J, Page GP, Bonvicini K, Woods SW, Pauls DL, Kruger S (2003) A chromosome 14 risk locus for simple phobia: results from a genomewide linkage scan. Mol Psychiatry 8: 71–82
George DT, Lindquist T, Nutt DJ et al (1995) Effect of chloride or glucose on the incidence of lactate-induced panic attacks. Am J Psychiatry 152: 692–697
Geraci M, Anderson TS, Slate-Cothren S, Post RM, McCann UD (2002) Pentagastrin-induced sleep panic attacks: panic in the absence of elevated baseline arousal. Biol Psychiatry 52: 1183–1189
Germine M, Goddard AW, Woods SW, Charney DS, Heninger GR (1992) Anger and anxiety responses to m-chlorophenylpiperazine in generalized anxiety disorder. Biol Psychiatry 32: 457–461
Gerra G, Zaimovic A, Zambelli U, Timpano M, Reali N, Bernasconi S, Brambilla F (2000) Neuroendocrine responses to psychological stress in adolescents with anxiety disorder. Neuropsychobiology 42: 82–92
Gloor P, Olivier A, Quesney LF, Andermann F, Horowitz S (1982) The role of the limbic system in experiential phenomena of temporal lobe epilepsy. Ann Neurol 12: 129–144
Goddard AW, Woods SW, Sholomskas DE, Goodman WK, Charney DS, Heninger GR (1993) Effects of the serotonin reuptake inhibitor fluvoxamine on yohimbine-induced anxiety in panic disorder. Psychiatry Res 48: 119–133
Goddard AW, Sholomskas DE, Walton KE et al (1994) Effects of tryptophan depletion in panic disorder. Biol Psychiatry 36: 775–777
Goddard AW, Woods SW, Money R et al (1999) Effects of the CCK(B) antagonist CI-988 on responses to mCPP in generalized anxiety disorder. Psychiatry Res 85: 225–240
Goddard AW, Brouette T, Almai A, Jetty P, Woods SW, Charney D (2001a) Early coadministration of clonazepam with sertraline for panic disorder. Arch Gen Psychiatry 58: 681–686
Goddard AW, Mason GF, Almai A et al (2001b) Reductions in occipital cortex GABA levels in panic disorder detected with 1h-magnetic resonance spectroscopy. Arch Gen Psychiatry 58: 556–561
Goldstein S, Halbreich U, Asnis G, Endicott J, Alvir J (1987) The hypothalamic-pituitary-adrenal system in panic disorder. Am J Psychiatry 144: 1320–1323
Gorman JM, Uy J (1987) Respiratory physiology and pathological anxiety. Gen Hosp Psychiatry 9: 410–419
Gorman JM, Askanazi J, Liebowitz MR, Fyer AJ, Stein J, Kinney JM, Klein DF (1984) Response to hyperventilation in a group of patients with panic disorder. Am J Psychiatry 141: 857–861
Gorman JM, Fyer MR, Goetz R et al (1988) Ventilatory physiology of patients with panic disorder. Arch Gen Psychiatry 45: 31–39
Gorman JM, Battista D, Goetz RR et al (1989) A comparison of sodium bicarbonate and sodium lactate infusion in the induction of panic attacks. Arch Gen Psychiatry 46: 145–150
Gorman JM, Papp LA, Coplan JD et al (1994) Anxiogenic effects of CO2 and hyperventilation in patients with panic disorder. Am J Psychiatry 151: 547–553
Gorman JM, Kent JM, Sullivan GM, Coplan JD (2000) Neuroanatomical hypothesis of panic disorder, revised. Am J Psychiatry 157: 493–505
Gratacos M, Nadal M, Martin-Santos R et al (2001) A polymorphic genomic duplication on human chromosome 15 is a susceptibility factor for panic and phobic disorders. Cell 106: 367–379
Griebel G, Perrault G, Sanger DJ (1998) Characterization of the behavioral profile of the non-peptide CRF receptor antagonist CP-154,526 in anxiety models in rodents. Comparison with diazepam and buspirone. Psychopharmacology 138: 55–66
Griez E, de Loof C, Pols H, Zandbergen J, Lousberg H (1990) Specific sensitivity of patients with panic attacks to carbon dioxide inhalation. Psychiatry Res 31: 193–199
Griffin LD, Mellon SH (1999) Selective serotonin reuptake inhibitors directly alter activity of neurosteroidogenic enzymes. Proc Natl Acad Sci USA 96: 13512–135217.
Grodd W, Schneider F, Klose U, Nagele T (1995) Functional magnetic resonance tomography of psychological functions exemplified by experimentally induced emotions. Radiologe 35: 283–289
Gross C, Zhuang X, Stark K et al (2002) Serotonin1A receptor acts during development to establish normal anxiety-like behaviour in the adult. Nature 416: 396–400
Grove G, Coplan JD, Hollander E (1997) The neuroanatomy of 5-HT dysregulation and panic disorder. J Neuropsychiatry Clin Neurosci 9: 198–207
Gurguis GN, Uhde TW (1990) Plasma 3-methoxy-4-hydroxyphenylethylene glycol (MHPG) and growth hormone responses to yohimbine in panic disorder patients and normal controls. Psychoneuroendocrinology 15: 217–224
Gurguis GN, Mefford IN, Uhde TW (1991) Hypothalamic-pituitary-adrenocortical activity in panic disorder: relationship to plasma catecholamine metabolites. Biol Psychiatry 30: 502–506
Hamilton SP, Heiman GA, Haghighi F et al (1999) Lack of genetic linkage or association between a functional serotonin transporter polymorphism and panic disorder. Psychiatr Genet 9: 1–6
Hamilton SP, Fyer AJ, Durner M, et al (2003) Further genetic evidence for a panic disorder syndrome mapping to chromosome 13q. Proc Natl Acad Sci USA 100: 2550–2555
Hamlin CL, Lydiard RB, Martin D, Dackis CA, Pottash AC, Sweeney D, Gold MS (1983) Urinary excretion of noradrenaline metabolite decreased in panic disorder. Lancet 2: 740–741
Handley SL (1995) 5-Hydroxytryptamine pathways in anxiety and its treatment. Pharmacol Ther 66: 103–148
Hariri AR, Mattay VS, Tessitore A et al (2002) Serotonin transporter genetic variation and the response of the human amygdala. Science 297: 400–403
Heils A, Teufel A, Petri S, Stober G, Riederer P, Bengel D, Lesch KP (1996) Allelic variation of human serotonin transporter gene expression. J Neurochem 66: 2621–2624
Heim C, Owens MJ, Plotsky PM, Nemeroff CB (1997) Persistent changes in corticotropin-releasing factor systems due to early life stress: relationship to the pathophysiology of major depression and posttraumatic stress disorder. Psychopharmacol Bull 33: 185–192
Hendrie CA, Neill JC, Shepherd JK, Dourish CT (1993) The effects of CCKA and CCKB antagonists on activity in the black/white exploration model of anxiety in mice. Physiol Behav 54: 689–693
Herman JP, Prewitt CM, Cullinan WE (1996) Neuronal circuit regulation of the hypothalamo-pituitary-adrenocortical stress axis. Crit Rev Neurobiol 10: 371–394
Hettema JM, Prescott CA, Kendler KS (2001) A population-based twin study of generalized anxiety disorder in men and women. J Nerv Ment Dis 189: 413–420
Hettema JM, Annas P, Neale MC, Kendler KS, Fredrikson M (2003) A twin study of the genetics of fear conditioning. Arch Gen Psychiatry 60: 702–708
Highley JD, King ST, Hasert MF, Champux M, Suomi SJ, Linnoila M (1996) Stability of interindividual differences in serotonin function and its relationship to severe aggression and competent social behaviour in rhesus macaque females. Neuropsychopharmacology 14: 67–76
Holsboer F (1999) The rationale for corticotropin-releasing hormone receptor (CRH-R) antagonists to treat depression and anxiety. J Psychiatr Res 33: 181–214
Holsboer F, Barden N (1996) Antidepressants and hypothalamic-pituitary-adrenocortical regulation. Endocr Rev 17: 187–205
Holsboer F, Spengler D, Heuser I (1992) The role of corticotropin-releasing hormone in the pathogenesis of Cushing’s disease, anorexia nervosa, alcoholism, affective disorders and dementia. Prog Brain Res 93: 385–417
Holt PE, Andrews G (1989) Provocation of panic: three elements of the panic reaction in four anxiety disorders. Behav Res Ther 27: 253–261
Hsiao JK, Potter WZ (1990) Mechanisms of action of antipanic drugs. In: Ballenger C (ed). Clinical aspects of panic disorder. Alan Liss, New York, pp 239–317
Huether G, Ruther E (2000) Das serotonerge System. Uni-med, Bremen
Inoue T, Tsuchiya K, Koyama T (1994) Regional changes in dopamine and serotonin activation with various intensity of physical and psychological stress in the rat brain. Pharmacol Biochem Behav 49: 911–920
Iny LJ, Pecknold J, Suranyi Cadotte BE, Bernier B, Luthe L, Nair NP, Meaney MJ (1994) Studies of a neurochemical link between depression, anxiety, and stress from [3H]imipramine and [3H]paroxetine binding on human platelets. Biol Psychiatry 36: 281–291
Ise K, Akiyoshi J, Horinouchi Y, Tsutsumi T, Isogawa K, Nagayama H (2003) Association between the CCK-A receptor gene and panic disorder. Am J Med Genet 118B: 29–31
Jabourian AP, Erlich M, Desvignes C, el Hadjam M, Bitton R (1992) Panic attacks and 24-hour ambulatory EEG monitoring. Ann Med Psychol 150: 240–245
Jang KL, Stein MB, Taylor S, Livesley WJ (1999) Gender differences in the etiology of anxiety sensitivity: a twin study. J Gend Specif Med 2: 39–44
Johnson MR, Lydiard RB (1995) The neurobiology of anxiety disorders. Psychiatr Clin N Am 18: 681–725
Johnson MR, Lydiard RB, Ballenger JC (1995) Panic disorder. Pathophysiology and drug treatment. Drugs 49: 328–344
Kandel ER (1999) Biology and the future of psychoanalysis: a new intellectual framework of psychiatry revisited. Am J Psychiatry 156: 505–524
Kaschka W, Feistel H, Ebert D (1995) Reduced benzodiazepine receptor binding in panic disorders measured by iomazenil SPECT. J Psychiatr Res 29: 427–434
Keck ME, Holsboer F (2001) Hyperactivity of CRH neuronal circuits as a target for therapeutic interventions in affective disorders. Peptides 22: 835–844
Kelsy JE, Selvig AL, Knight BT (2000) Treatment of generalized anxiety disorder social phobia with the 5HT2 antagonist nefazodone. Anxiety disorders of America’s 20th annual conference, Washington DC
Kendler KS, Neale MC, Kessler RC, Heath AC, Eaves LJ (1992) The genetic epidemiology of phobias in women. The interrelationship of agoraphobia, social phobia, situational phobia, and simple phobia. Arch Gen Psychiatry 49: 273–281
Kendler KS, Neale MC, Kessler RC, Heath AC, Eaves LJ (1993) Panic disorder in women: a population-based twin study. Psychol Med 23: 397–406
Kendler KS, Walters EE, Neale MC, Kessler RC, Heath AC, Eaves LJ (1995) The structure of the genetic and environmental risk factors for six major psychiatric disorders in women. Phobia, generalized anxiety disorder, panic disorder, bulimia, major depression, and alcoholism. Arch Gen Psychiatry 52: 374–383
Kendler KS, Jacobson KC, Myers J, Prescott CA (2002) Sex differences in genetic and environmental risk factors for irrational fears and phobias. Psychol Med 32: 209–217
Kennedy JL, Bradwejn J, Koszycki D, King N, Crowe R, Vincent J, Fourie O (1999) Investigation of cholecystokinin system genes in panic disorder. Mol Psychiatry 4: 284–285
Kennedy JL, Neves-Pereira M, King N, Lizak MV, Basile VS, Chartier MJ, Stein MB (2001) Dopamine system genes not linked to social phobia. Psychiatr Genet 11: 213–217
Klein D (1964) Delineation of two drug-responsive anxiety syndromes. Psychopharmacology 5: 397–408
Klein DF (1993) False suffocation alarms, spontaneous panics, and related conditions. An integrative hypothesis. Arch Gen Psychiatry 50: 306–317
Klein E, Zohar J, Geraci MF, Murphy DL, Uhde TW (1991) Anxiogenic effects of m-CPP in patients with panic disorder: comparison to caffeine’s anxiogenic effects. Biol Psychiatry 30: 973–984
Knowles JA, Fyer AJ, Vieland VJ et al (1998) Results of a genome-wide genetic screen for panic disorder. Am J Med Genet 81: 139–147
Knutson B, Wolkowitz OM, Cole SW et al (1998) Selective alteration of personality and social behavior by serotonergic intervention. Am J Psychiatry 155: 373–379
Koenigsberg HW, Pollak CP, Fine J, Kakuma T (1994) Cardiac and respiratory activity in panic disorder: effects of sleep and sleep lactate infusions. Am J Psychiatry 151: 1148–1152
Kramer MS, Cutler NR, Ballenger JC et al (1995) A placebo-controlled trial of L-365,260, a CCKB antagonist, in panic disorder. Biol Psychiatry 37: 462–466
Krystal JH, Niehoff Deutsch D, Charney DS (1996) The biological basis of panic disorder. J Clin Psychiatry 57: 23–33
Kuboki T, Suematsu H (1992) Panic disorder. Nippon Rinsho 50: 2773–2782
Kuikka JT, Pitkanen A, Lepola U et al (1995) Abnormal regional benzodiazepine receptor uptake in the prefrontal cortex in patients with panic disorder. Nucl Med Commun 16: 273–280
LaBar KS, Gatenby JC, Gore JC, LeDoux JE, Phelps EA (1998) Human amygdala activation during conditioned fear acquisition and extinction: a mixed-trial fMRI study. Neuron 20: 937–945
Last CG, Hersen M, Kazdin A, Orvaschel H, Perrin S (1991) Anxiety disorders in children and their families. Arch Gen Psychiatry 48: 928–934
Lauer CJ, Krieg JC (1992) Sleep electroencephalographic patterns and cranial computed tomography in anxiety disorders. Compr Psychiatry 33: 213–219
LeDoux JE, Cicchetti P, Xagoraris A, Romanski LM (1990) The lateral amygdaloid nucleus: sensory interface of the amygdala in fear conditioning. J Neurosci 10: 1062–1069
Lepola U, Nousiainen U, Puranen M, Riekkinen P, Rimon R (1990) EEG and CT findings in patients with panic disorder. Biol Psychiatry 28: 721–727
Lesch KP, Wiesmann M, Hoh A et al (1992) 5-HT1A receptor-effector system responsivity in panic disorder. Psychopharmacology 106: 111–117
Levin AP, Saoud J, Struaman T, Gorman JM, Fyer AJ, Crawford R, Liebowitz MR (1993) Responses of generalized and discrete social phobics during public speaking. J Anxiety Disord 7: 207–221
Li D, Chokka P, Tibbo P (2001) Toward an integrative understanding of social phobia. J Psychiatry Neurosci 26: 190–202
Li YW, Hill G, Wong H et al (2003) Receptor occupancy of nonpeptide corticotropin-releasing factor 1 antagonist DMP696: correlation with drug exposure and anxiolytic efficacy. J Pharmacol Exp Ther 305: 86–96
Liebowitz MR, Gorman JM, Fyer AJ, Dillon DJ, Klein DF (1984) Effects of naloxone on patients with panic attacks. Am J Psychiatry 141: 995–997
Liebowitz MR, Fyer AJ, Gorman JM et al (1985) Specificity of lactate infusions in social phobia versus panic disorders. Am J Psychiatry 142: 947–950
Liebsch G, Landgraf R, Engelmann M, Lorscher P, Holsboer F (1999) Differential behavioural effects of chronic infusion of CRH 1 and CRH 2 receptor antisense oligonucleotides into the rat brain. J Psychiatr Res 33: 153–163
Liu D, Diorio J, Tannenbaum B et al (1997) Maternal care, hippocampal glucocorticoid receptors, and hypothalamic-pituitary-adrenal responses to stress. Science 277: 1659–1662
Lydiard RB, Ballenger JC, Laraia MT, Fossey MD, Beinfeld MC (1992) CSF cholecystokinin concentrations in patients with panic disorder and in normal comparison subjects. Am J Psychiatry 149: 691–693
Lydiard RB, Morton WA, Emmanuel NP et al (1993) Preliminary report: placebo-controlled, double-blind study of the clinical and metabolic effects of desipramine in panic disorder. Psychopharmacol Bull 29: 183–188
MacKinnon DF, Xu J, McMahon FJ, Simpson SG, Stine OC, McInnis MG, DePaulo JR (1998) Bipolar disorder and panic disorder in families: an analysis of chromosome 18 data. Am J Psychiatry 155: 829–831
Maddon KS, Felten DL (1995) Experimental basis for neuroimmune interactions. Physiol Rev 75: 77–106
Malizia AL, Wilson SJ, Bell CM, Nutt DJ, Grasby PM (1997) Neural correlates of anxiety provocation in social phobia. Neuroimage 5: 301–305
Malizia AL, Cunningham VJ, Bell CJ, Liddle PF, Jones T, Nutt DJ (1998) Decreased brain GABA(A)-benzodiazepine receptor binding in panic disorder: preliminary results from a quantitative PET study. Arch Gen Psychiatry 55: 715–720
Marazziti D, Rotondo A, Martini C et al (1994) Changes in peripheral benzodiazepine receptors in patients with panic disorder and obsessive-compulsive disorder. Neuropsychobiology 29: 8–11
Maremmani I, Marini G, Fornai F (1998) Naltrexone-induced panic attacks. Am J Psychiatry 155: 447
Martin-Santos R, Bulbena A, Prta M, Gago J, Molina L, Duró JC (1998) Association between joint hypermobility syndrome and panic disorder. Am J Psychiatry 155: 1578–1583
Martins AP, Marras RA, Guimaraes FS (2000) Anxiolytic effect of a CRH receptor antagonist in the dorsal periaqueductal gray. Depress Anxiety 12: 99–101
Massana G, Serra-Grabulosa JM, Salgado-Pineda P, Gasto C, Junque C, Massana J, Mercader JM (2003) Parahippocampal gray matter density in panic disorder: a voxel-based morphometric study. Am J Psychiatry 160: 566–568
Mathew S, Coplan JD (2004) Animal models of social anxiety. In: Bandelow B, Stein DJ (eds) Social anxiety disorder. Marcel Dekker, New York
Mathew RJ, Ho BT, Kralik P, Taylor D, Semchuk K, Weinman M, Claghorn JL (1980) Catechol-O-methyltransferase and catecholamines in anxiety and relaxation. Psychiatry Res 3: 85–91
Mathew RJ, Ho BT, Francis DJ, Taylor DL, Weinman ML (1982) Catecholamines and anxiety. Acta Psychiatr Scand 65: 142–147
Mathews AM, Wilson WH (1987) Cerebral blood flow changes. Psychiatry Res 23: 285–294
Mavissakalian M, Perel J, Bowler K, Dealy R (1987) Trazodone in the treatment of panic disorder and agoraphobia with panic attacks. Am J Psychiatry 144: 785–787
McCann UD, Morgan CM, Geraci M, Slate SO, Murphy DL, Post RM (1997) Effects of the 5-HT3 antagonist, ondansetron, on the behavioral and physiological effects of pentagastrin in patients with panic disorder and social phobia. Neuropsychopharmacology 17: 360–369
McEwen B (1999a) The effects of stress on structural and functional plasticity in the hippocampus. In: Charney D (ed) Neurobiology of mental illness. Oxford University Press, Oxford, pp 475–493
McEwen BS (1999b) Stress and the aging hippocampus. Front Neuroendocrinol 20: 49–70
McIntyre IM, Judd FK, Marriott PM, Burrows GD, Norman TR (1989) Plasma melatonin levels in affective states. Int J Clin Pharmacol Res 9: 159–164
Menzies RG, Clarke JC (1993) The etiology of fear of heights and its relationship to severity and individual response patterns. Behav Res Ther 31: 355–365
Miner CM, Davidson JR, Potts NL, Tupler LA, Charles HC, Krishnan KR (1995) Brain fluoxetine measurements using fluorine magnetic resonance spectroscopy in patients with social phobia. Biol Psychiatry 38: 696–698
Mohler H, Fritschy JM, Rudolph U (2002) A new benzodiazepine pharmacology. J Pharmacol Exp Ther 300: 2–8
Montkowsky A, Jahn H, Ströhle A et al (1998) C-type natriueretic peptide exerts opposing effecs to atrial natriuretic peptide on anxietyrelated behaviour in rats. Brain Res 792: 358–360
Morgan MA, LeDoux JE (1995) Differential contribution of dorsal and ventral medial prefrontal cortex to the acquisition and extinction of conditioned fear in rats. Behav Neurosci 109: 681–688
Morris JS, Frith CD, Perrett DI, Rowland D, Young AW, Calder AJ, Dolan RJ (1996) A differential neural response in the human amygdala to fearful and happy facial expressions. Nature 383: 812–815
Mountz JM, Modell JG, Wilson MW, Curtis GC, Lee MA, Schmaltz S, Kuhl DE (1989) Positron emission tomographic evaluation of cerebral blood flow during state anxiety in simple phobia. Arch Gen Psychiatry 46: 501–504
Müller N, Schwarz MJ (2003) Immunology in anxiety and depression. In: Kasper S, Sitsen JM (eds) Handbook of depression and anxiety. Marcel Dekker, New York, pp 267–288
Munck A, Guyre PM, Holbrook NJ (1984) Physiological functions of glucocorticoids in stress and their relation to pharmacological actions. Endocr Rev 5: 25–44
Munjack DJ, Baltazar PL, DeQuattro V et al (1990) Generalized anxiety disorder: some biochemical aspects. Psychiatry Res 32: 35–43
Murphy BE, Filipini D, Ghadirian AM (1993) Possible use of glucocorticoid receptor antagonists in the treatment of major depression: preliminary results using RU 486. J Psychiatry Neurosci 18: 209–213
Nardi AE, Nascimento I, Valenca AM, Lopes FL, Zin WA, Mezzasalma MA, Versiani M (2002) A breath-holding challenge in panic disorder patients, their healthy first-degree relatives, and normal controls. Respir Physiol Neurobiol 133: 43–47
Nesse RM, Cameron OG, Curtis GC, McCann DS, Huber Smith MJ (1984) Adrenergic function in patients with panic anxiety. Arch Gen Psychiatry 41: 771–776
Nesse RM, Cameron OG, Buda AJ, McCann DS, Curtis GC, Huber Smith MJ (1985a) Urinary catecholamines and mitral valve prolapse in panic-anxiety patients. Psychiatry Res 14: 67–75
Nesse RM, Curtis GC, Thyer BA, McCann DS, Huber-Smith MJ, Knopf RF (1985b) Endocrine and cardiovascular responses during phobic anxiety. Psychosom Med 47: 320–332
Nieuwenhuys R, Voogd J, van Huijzen C (1991) Das Zentralnervensystem des Menschen. Springer, Berlin Heidelberg New York
Nordahl TE, Semple WE, Gross M et al (1990) Cerebral glucose metabolic differences in patients with panic disorder. Neuropsychopharmacology 3: 261–272
Noyes R Jr., Clarkson C, Crowe RR, Yates WR, McChesney CM (1987) A family study of generalized anxiety disorder. Am J Psychiatry 144: 1019–10124
Nutt DJ (1989) Altered central alpha2-adrenoceptor sensitivity in panic disorder. Arch Gen Psychiatry 46: 165–169
Nutt DJ (2001) Neurobiological mechanisms in generalized anxiety disorder. J Clin Psychiatry 62: 22–28
Nutt DJ, Glue P, Lawson C, Wilson S (1990) Flumazenil provocation of panic attacks. Evidence for altered benzodiazepine receptor sensitivity in panic disorder. Arch Gen Psychiatry 47: 917–925
Nutt DJ, Forshall S, Bell C, Rich A, Sandford J, Nash J, Argyropoulos S (1999) Mechanisms of action of selective serotonin reuptake inhibitors in the treatment of psychiatric disorders. Eur Neuropsychopharmacol 9: S81–86.
O’Carroll RE, Moffoot AP, Van Beck M, Dougall N, Murray C, Ebmeier KP, Goodwin GM (1993) The effect of anxiety induction on the regional uptake of 99mTc-exametazime in simple phobia as shown by single photon emission tomography (SPET). J Affect Disord 28: 203–210
Ollendick TH, Hirshfeld-Becker DR (2002) The developmental psychopathology of social anxiety disorder. Biol Psychiatry 51: 44–58
Ontiveros A, Fontaine R, Breton G, Elie R, Fontaine S, Dery R (1989) Correlation of severity of panic disorder and neuroanatomical changes on magnetic resonance imaging. J Neuropsychiatr Clin Neurosci 1: 404–408
Papp LA, Klein DF, Gorman JM (1993a) Carbon dioxide hypersensitivity, hyperventilation, and panic disorder. Am J Psychiatry 150: 1149–1157
Papp LA, Klein DF, Martinez J et al (1993b) Diagnostic and substance specificity of carbon-dioxide-induced panic. Am J Psychiatry 150: 250–257
Pavlov IP (1927) Conditioned reflexes: an investigation of the physiological activity of the cerebral cortex. Edited by Anrep GV (1960). Boyer, New York
Pelletier G, Steinbusch HW, Verhofstad AA (1981) Immunoreactive substance P and serotonin present in the same dense-core vesicles. Nature 293: 71–72
Perna G, Bertani A, Caldirola D, Bellodi L (1996) Family history of panic disorder and hypersensitivity to CO2 in patients with panic disorder. Am J Psychiatry 153: 1060–1064
Perna G, Caldirola D, Arancio C, Bellodi L (1997) Panic attacks: a twin study. Psychiatry Res 66: 69–71
Perna G, Bussi R, Allevi L, Bellodi L (1999) Sensitivity to 35% carbon dioxide in patients with generalized anxiety disorder. J Clin Psychiatry 60: 379–384
Pichot W, Hansenne M, Gonzalez Moreno A, Ansseau M (1995) Growth hormone response to apomorphine in panic disorder: comparison with major depression and normal controls. Eur Arch Psychiatry Clin Neurosci 245: 306–308
Pigott TA (1999) Gender differences in the epidemiology and treatment of anxiety disorders. J Clin Psychiatry 60: 4–15
Pitts F, McClure J (1967) Lactate metabolism in anxiety neurosis. New Engl J Med 277: 1329–1340
Plotsky PM, Meaney MJ (1993) Early, postnatal experience alters hypothalamic corticotropin-releasing factor (CRF) mRNA, median eminence CRF content and stress-induced release in adult rats. Brain Res Mol Brain Res 18: 195–200
Pohl R, Ettedgui E, Bridges M, Lycaki H, Jimerson D, Kopin I, Rainey JM (1987) Plasma MHPG levels in lactate and isoproterenol anxiety states. Biol Psychiatry 22: 1127–1136
Pohl R, Yeragani V, Balon R et al (1988) Isoproterenol-induced panic attacks. Biol Psychiatry 42: 891–902
Potts NL, Book S, Davidson JR (1996) The neurobiology of social phobia. Int Clin Psychopharmacol 11: 43–48
Pyke RE, Greenberg HS (1986) Norepinephrine challenges in panic patients. J Clin Psychopharmacol 6: 279–285
Quesney LF (1986) Clinical and EEG features of complex partial seizures of temporal lobe origin. Epilepsia 27: S27–45
Radulovic J, Ruhmann A, Liepold T, Spiess J (1999) Modulation of learning and anxiety by corticotropin-releasing factor (CRF) and stress: differential roles of CRF receptors 1 and 2. J Neurosci 19: 5016–5025
Rainey JM Jr., Pohl RB, Williams M, Knitter E, Freedman RR, Ettedgui E (1984a) A comparison of lactate and isoproterenol anxiety states. Psychopathology 17: 74–82
Rainey M Jr., Ettedgui E, Pohl B, Balon R, Weinberg P, Yelonek S, Berchou R (1984b) The beta-receptor: isoproterenol anxiety states. Psychopathology 17: 40–51
Raleigh MJ, Brammer GL, McGuire MT, Yuwiler A (1985) Dominant social status facilitates the behavioural effects of serotonergic agonists. Brain Res 348: 274–282
Rapaport MH (1998) Circulating lymphocyte phenotypic surface markers in anxiety disorder patients and normal volunteers. Biol Psychiatry 43: 458–463
Rauch SL, Savage CR, Alpert NM et al (1995) A positron emission tomographic study of simple phobic symptom provocation. Arch Gen Psychiatry 52: 20–28
Reich J, Yates W (1988) Family history of psychiatric disorders in social phobia. Compr Psychiatry 29: 72–75
Reiman EM (1997) The application of positron emission tomography to the study of normal and pathologic emotions. J Clin Psychiatry 58: 4–12
Reiman EM, Raichle ME, Butler FK, Herscovitch P, Robins E (1984) A focal brain abnormality in panic disorder, a severe form of anxiety. Nature 310: 683–685
Reiman EM, Raichle ME, Robins E, Butler FK, Herscovitch P, Fox P, Perlmutter J (1986) The application of positron emission tomography to the study of panic disorder. Am J Psychiatry 143: 469–477
Reiman EM, Raichle ME, Robins E et al (1989) Neuroanatomical correlates of a lactate-induced anxiety attack. Arch Gen Psychiatry 46: 493–500
Rickels K, Schweizer E, DeMartinis N, Mandos L, Mercer C (1997) Gepirone and diazepam in generalized anxiety disorder: a placebo-controlled trial. J Clin Psychopharmacol 17: 272–277
Rocca P, Ferrero P, Gualerzi A, Zanalda E, Maina G, Bergamasco B, Ravizza L (1991) Peripheral-type benzodiazepine receptors in anxiety disorders. Acta Psychiatr Scand 84: 537–544
Rose RJ, Ditto WB (1983) A developmental-genetic analysis of common fears from early adolescence to early adulthood. Child Devel 54: 361–368
Rosenbaum AH, Schatzberg AF, Jost FA, Cross PD, Wells LA, Jiang NS, Maruta T (1983) Urinary free cortisol levels in anxiety. Psychosomatics 24: 835–837
Rosenbaum JF, Biederman J, Bolduc EA, Hirshfeld DR, Faraone SV, Kagan J (1992) Comorbidity of parental anxiety disorders as risk for childhood-onset anxiety in inhibited children. Am J Psychiatry 149: 475–481
Rotondo A, Mazzanti C, Dell’Osso L et al (2002) Catechol o-methyltransferase, serotonin transporter, and tryptophan hydroxylase gene polymorphisms in bipolar disorder patients with and without comorbid panic disorder. Am J Psychiatry 159: 23–29
Roy MA, Neale MC, Pedersen NL, Mathe AA, Kendler KS (1995) A twin study of generalized anxiety disorder and major depression. Psychol Med 25: 1037–1049
Roy-Byrne PP, Uhde TW, Post RM, Gallucci W, Chrousos GP, Gold PW (1986a) The corticotropin-releasing hormone stimulation test in patients with panic disorder. Am J Psychiatry 143: 896–899
Roy-Byrne PP, Uhde TW, Sack DA, Linnoila M, Post RM (1986b) Plasma HVA and anxiety in patients with panic disorder. Biol Psychiatry 21: 849–853
Roy-Byrne PP, Cowley DS, Greenblatt DJ, Shader RI, Hommer D (1990) Reduced benzodiazepine sensitivity in panic disorder. Arch Gen Psychiatry 47: 534–538
Roy-Byrne PP, Wingerson DK, Radant A, Greenblatt DJ, Cowley DS (1996) Reduced benzodiazepine sensitivity in patients with panic disorder: comparison with patients with obsessive-compulsive disorder and normal subjects. Am J Psychiatry 153: 1444–1449
Rupprecht R, Zwanzger P (2003) Significance of GABA-A receptors for the pathophysiology and therapy of panic disorders. Nervenarzt 74: 543–551
Sand PG, Mori T, Godau C et al (2002) Norepinephrine transporter gene (NET) variants in patients with panic disorder. Neurosci Lett 333: 41–44
Sasson Y, Iancu I, Fux M, Taub M, Dannon PN, Zohar J (1999) A double-blind crossover comparison of clomipramine and desipramine in the treatment of panic disorder. Eur Neuropsychopharmacol 9: 191–196
Schlegel S, Steinert H, Bockisch A, Hahn K, Schloesser R, Benkert O (1994) Decreased benzodiazepine receptor binding in panic disorder measured by IOMAZENIL-SPECT. A preliminary report. Eur Arch Psychiatry Clin Neurosci 244: 49–51
Schneider P, Evans L, Ross Lee L, Wiltshire B, Eadie M, Kenardy J, Hoey H (1987) Plasma biogenic amine levels in agoraphobia with panic attacks. Pharmacopsychiatry 20: 102–104
Schneider F, Weiss U, Kessler C et al (1999) Subcortical correlates of differential classical conditioning of aversive emotional reactions in social phobia. Biol Psychiatry 45: 863–871
Schneier FR, Liebowitz MR, Abi-Dargham A, Zea-Ponce Y, Lin SH, Laruelle M (2000) Low dopamine D(2) receptor binding potential in social phobia. Am J Psychiatry 157: 457–459
Schwartz CE, Wright CI, Shin LM, Kagan J, Rauch SL (2003) Inhibited and uninhibited infants »grown up«: adult amydgdalar response to novelty. Science 300: 1952–1953
Seibyl JP, Krystal JH, Price LH, Woods SW, D’Amico C, Heninger GR, Charney DS (1991) Effects of ritanserin on the behavioral, neuroendocrine, and cardiovascular responses to meta-chlorophenylpiperazine in healthy human subjects. Psychiatry Res 38: 227–236
Seligman MEP (1971) Phobias and preparedness. Behav Ther 2: 307–320
Sevy S, Papadimitriou GN, Surmont DW, Goldman S, Mendlewicz J (1989) Noradrenergic function in generalized anxiety disorder, major depressive disorder, and healthy subjects. Biol Psychiatry 25: 141–152
Seymour PA, Schmidt AW, Schulz DW (2003) The pharmacology of CP-154, 526, a non-peptide antagonist of the CRH1 receptor: a review. CNS Drug Rev 9: 57–96
Shlik J, Aluoja A, Vasar V, Vasar E, Podar T, Bradwejn J (1997) Effects of citalopram treatment on behavioural, cardiovascular and neuroendocrine response to cholecystokinin tetrapeptide challenge in patients with panic disorder. J Psychiatry Neurosci 22: 332–340
Skre I, Onstad S, Torgersen S, Lygren S, Kringlen E (1993) A twin study of DSM-III-R anxiety disorders. Acta Psychiatr Scand 88: 85–92
Smagin GN, Swiergiel AH, Dunn AJ (1995) Corticotropin-releasing factor administered into the locus coeruleus, but not the parabrachial nucleus, stimulates norepinephrine release in the prefrontal cortex. Brain Res Bull 36: 71–76
Smoller JW, Tsuang MT (1998) Panic and phobic anxiety: defining phenotypes for genetic studies. Am J Psychiatry 155: 1152–1162
Sramek JJ, Costa JF, Adams JB, Macpherson A, Cutler NR (1994) Singlesite findings in a study of the safety and efficacy of a CCKB receptor antagonist, CI-988, in the treatment of generalized anxiety disorder. Anxiety 1: 242–243
Stein MB, Leslie WD (1996) A brain single photon-emission computed tomography (SPECT) study of generalized social phobia. Biol Psychiatry 39: 825–828
Stein MB, Tancer ME, Uhde TW (1992) Heart rate and plasma norepinephrine responsivity to orthostatic challenge in anxiety disorders. Comparison of patients with panic disorder and social phobia and normal control subjects. Arch Gen Psychiatry 49: 311–317
Stein MB, Asmundson GJ, Chartier M (1994) Autonomic responsivity in generalized social phobia. J Affect Disord 31: 211–221
Stein MB, Delaney SM, Chartier MJ, Kroft CD, Hazen AL (1995) [3H]paroxetine binding to platelets of patients with social phobia: comparison to patients with panic disorder and healthy volunteers. Biol Psychiatry 37: 224–228
Stein MB, Jang KL, Livesley WJ (1999) Heritability of anxiety sensitivity: a twin study. Am J Psychiatry 156: 246–251
Stein MB, Goldin PR, Sareen J, Zorrilla LT, Brown GG (2002) Increased amygdala activation to angry and contemptuous faces in generalized social phobia. Arch Gen Psychiatry 59: 1027–1034
Stemberger RT, Turner SM, Beidel DC, Calhoun KS (1995) Social phobia: an analysis of possible developmental factors. J Abnorm Psychol 104: 526–531
Stewart RS, Devous MD Sr., Rush AJ, Lane L, Bonte FJ (1988) Cerebral blood flow changes during sodium-lactate-induced panic attacks. Am J Psychiatry 145: 442–449
Strörle A, JAhn H, Montkowki A et al (1997) Central and peripheral administration of atriopeptin is anxiolytic in rats. Neuroendocrinology 65: 210–215
Ströhle A, Kellner M, Yassouridis A, Holsboer F, Wiedemann K (1998) Effect of flumazenil in lactate-sensitive patients with panic disorder. Am J Psychiatry 155: 610–612
Ströhle A, Kellner M, Holsboer F, Wiedemann K (2001) Anxiolytic activity of atrial natriuretic peptide in patients with panic disorder. Am J Psychiatry 158: 1514–1516
Ströhle A, Romeo E, di Michele F, Pasini A, Yassouridis A, Holsboer F, Rupprecht R (2002) GABA(A) receptor-modulating neuroactive steroid composition in patients with panic disorder before and during paroxetine treatment. Am J Psychiatry 159: 145–147
Ströhle A, Romeo E, di Michele F et al (2003) Induced panic attacks shift gamma-aminobutyric acid type A receptor modulatory neuroactive steroid composition in patients with panic disorder: preliminary results. Arch Gen Psychiatry 60: 161–168
Stutzmann GE, LeDoux JE (1999) GABAergic antagonists block the inhibitory effects of serotonin in the lateral amygdala: a mechanism for modulation of sensory inputs related to fear conditioning. J Neurosci (Online) 19: RC8.
Sullivan GM, Coplan JD, Gorman JM (1998) Psychoneuroendocrinology of anxiety disorders. Psychiatr Clin N Am 21: 397–412
Svensson T, Usdin T (1978) Feedback inhibition of brain noradrenaline neurons by tricyclic antidepressants α2 receptor mediation. Science 202: 1089–1091
Tancer ME, Stein MB, Uhde TW (1993) Growth hormone response to intravenous clonidine in social phobia: comparison to patients with panic disorder and healthy volunteers. Biol Psychiatry 34: 591–595
Tancer ME, Stein MB, Uhde TW (1994) Lactic acid response to caffeine in panic disorder: comparison with social phobics and normal controls. Anxiety 1: 138–140
Targum SD (1990) Differential responses to anxiogenic challenge studies in patients with major depressive disorder and panic disorder. Biol Psychiatry 28: 21–34
Targum SD (1992) Cortisol response during different anxiogenic challenges in panic disorder patients. Psychoneuroendocrinology 17:453–458
Targum SD, Marshall LE (1989) Fenfluramine provocation of anxiety in patients with panic disorder. Psychiatry Res 28: 295–306
Taylor S (1998) The hierarchic structure of fears. Behav Res Ther 36: 205–214
Thiebot MH, Hamon M, Soubrie P (1982) Attenuation of induced-anxiety in rats by chlordiazepoxide: role of raphe dorsalis benzodiazepine binding sites and serotoninergic neurons. Neuroscience 7: 2287–2294
Tiihonen J, Kuikka J, Bergstrom K, Lepola U, Koponen H, Leinonen E (1997) Dopamine reuptake site densities in patients with social phobia. Am J Psychiatry 154: 239–242
Tiller JW, Biddle N, Maguire KP, Davies BM (1988) The dexamethasone suppression test and plasma dexamethasone in generalized anxiety disorder. Biol Psychiatry 23: 261–270
Tiller JW, Bouwer C, Behnke K (1999) Moclobemide and fluoxetine for panic disorder. International Panic Disorder Study Group. Eur Arch Psychiatry Clin Neurosci 249: S7–10
Tillfors M, Furmark T, Marteinsdottir I, Fredrikson M (2002) Cerebral blood flow during anticipation of public speaking in social phobia: a PET study. Biol Psychiatry 52: 1113–1119
Timpl P, Spanagel R, Sillaber I et al (1998) Impaired stress response and reduced anxiety in mice lacking a functional corticotropin-releasing hormone receptor 1110. Nature Genet 19: 162–166
Torgersen S (1979) The nature and origin of common phobic fears. Br J Psychiatry 134: 343–351
Torgersen S (1983) Genetic factors in anxiety disorders. Arch Gen Psychiatry 40: 1085–1089
Törk I, Hornung JP (1990) Raphe nuclei and the serotonergic system. In: Paxinos G, Orlando FL (eds) The human nervous system. Academic Press, San Diego, pp 1001–1022
Tupler LA, Davidson JR, Smith RD, Lazeyras F, Charles HC, Krishnan KR (1997) A repeat proton magnetic resonance spectroscopy study in social phobia. Biol Psychiatry 42: 419–424
Uhde TW, Vittone BJ, Siever LJ, Kaye WH, Post RM (1986) Blunted growth hormone response to clonidine in panic disorder patients. Biol Psychiatry 21: 1081–1085
Uhde TW, Berrettini WH, Roy Byrne PP, Boulenger JP, Post RM (1987) Platelet [3H]imipramine binding in patients with panic disorder. Biol Psychiatry 22: 52–58
Uhde TW, Stein MB, Vittone BJ, Siever LJ, Boulenger JP, Klein E, Mellman TA (1989) Behavioral and physiologic effects of short-term and long-term administration of clonidine in panic disorder. Arch Gen Psychiatry 46: 170–177
Uhde TW, Tancer ME, Gelernter CS, Vittone BJ (1994) Normal urinary free cortisol and postdexamethasone cortisol in social phobia: comparison to normal volunteers. J Affect Disord 30: 155–161
van Ameringen M, Mancini C (2004) The promise of neurobiology in social anxiety disorder. In: Bandelow B, Stein DJ (eds) Social anxiety disorder. Marcel Dekker, New York
van Ameringen M, Mancini C, Oakman JM, Kamath M, Nahmias C, Szechtman HA (1998) Pilot study of PET in social phobia. Biol Psychiatry 43: 31–37
van der Linden GJ, Stein DJ, van Balkom AJ (2000) The efficacy of the selective serotonin reuptake inhibitors for social anxiety disorder (social phobia): a meta-analysis of randomized controlled trials. Int Clin Psychopharmacol 15: S15–23
van Megen HJ, Westenberg HG, den Boer JA, Slaap B, van Es Radhakishun F, Pande AC (1997) The cholecystokinin-B receptor antagonist CI-988 failed to affect CCK-4 induced symptoms in panic disorder patients. Psychopharmacology 129: 243–248
van Vliet I, den Boer JA, Westenberg HGM (1994) Psychopharmacological treatment of social phobia — a double blind placebo controlled study with fluvoxamine. Psychopharmacology 115: 128–134
van Vliet IM, Westenberg HG, den Boer JA (1996) Effects of the 5-HT1A receptor agonist flesinoxan in panic disorder. Psychopharmacology 127: 174–180
Veit R, Flor H, Erb M, Hermann C, Lotze M, Grodd W, Birbaumer N (2002) Brain circuits involved in emotional learning in antisocial behavior and social phobia in humans. Neurosci Lett 328: 233–236
Veltman DJ, van Zijderveld GA, van Dyck R (1996) Epinephrine infusions in panic disorder: a double-blind placebo-controlled study. J Affect Disord 39: 133–140
Verburg K, Griez E, Meijer J, Pols H (1995) Discrimination between panic disorder and generalized anxiety disorder by 35% carbon dioxide challenge. Am J Psychiatry 152: 1081–1083
Versiani M, Cassano G, Perugi G, Benedetti A, Mastalli L, Nardi A, Savino M (2002) Reboxetine, a selective norepinephrine reuptake inhibitor, is an effective and well-tolerated treatment for panic disorder. J Clin Psychiatry 63: 31–37
Viana MB, Graeff FG, Loschmann PA (1997) Kainate microinjection into the dorsal raphe nucleus induces 5-HT release in the amygdala and periaqueductal gray. Pharmacol Biochem Behav 58: 167–172
Vieland VJ, Goodman DW, Chapman T, Fyer AJ (1996) New segregation analysis of panic disorder. Am J Med Genet 67: 147–153
Villacres EC, Hollifield M, Katon WJ, Wilkinson CW, Veith RC (1987) Sympathetic nervous system activity in panic disorder. Psychiatry Res 21: 313–321
Wedekind D, Bandelow B, Broocks A, Hajak G, Ruther E (2000) Salivary, total plasma and plasma free cortisol in panic disorder. J Neural Transm 107: 831–837
Weissman MM, Fyer AJ, Haghighi F et al (2000) Potential panic disorder syndrome: clinical and genetic linkage evidence. Am J Med Genet 96: 24–35
Weizman R, Tanne Z, Granek M, Karp L, Golomb M, Tyano S, Gavish M (1987) Peripheral benzodiazepine binding sites on platelet membranes are increased during diazepam treatment of anxious patients. Eur J Pharmacol 138: 289–292
Welkowitz LA, Papp L, Martinez J, Browne S, Gorman JM (1999) Instructional set and physiological response to CO2 inhalation. Am J Psychiatry 156: 745–748
Westberg P, Modigh K, Lisjo P, Eriksson E (1991) Higher postdexamethasone serum cortisol levels in agoraphobic than in nonagoraphobic panic disorder patients. Biol Psychiatry 30: 247–256
Wik G, Fredrikson M, Fischer H (1997) Evidence of altered cerebral blood-flow relationships in acute phobia. Int J Neurosci 91: 253–263
Wilkinson DJ, Thompson JM, Lambert GW et al (1998) Sympathetic activity in patients with panic disorder at rest, under laboratory mental stress, and during panic attacks. Arch Gen Psychiatry 55: 511–520
Woo JM, Yoon KS, Yu BH (2002) Catechol O-methyltransferase genetic polymorphism in panic disorder. Am J Psychiatry 159: 1785–1787
Wood SJ, Toth M (2001) Molecular pathways of anxiety revealed by knockout mice. Mol Neurobiol 23: 101–119
Woods SW, Charney DS, Goodman WK, Heninger GR (1988a) Carbon dioxide-induced anxiety. Behavioral, physiologic, and bioche mical effects of carbon dioxide in patients with panic disorders and healthy subjects. Arch Gen Psychiatry 45: 43–52
Woods SW, Koster K, Krystal JK, Smith EO, Zubal IG, Hoffer PB, Charney DS (1988b) Yohimbine alters regional cerebral blood flow in panic disorder. Lancet 2: 678
Woods SW, Charney DS, Silver JM, Krystal JH, Heninger GR (1991) Behavioral, biochemical, and cardiovascular responses to the benzodiazepine receptor antagonist flumazenil in panic disorder. Psychiatry Res 36: 115–127
Wu J, Buchsbaum M, Hershey T, Hazlett E, Sciotte N, Johnson J (1991) PET in generalized anxiety disorder. Biol Psychiatry 29: 1181–1199
Wurthmann C, Bogerts B, Gregor J, Baumann B, Effenberger O, Dohring W (1997) Frontal CSF enlargement in panic disorder: a qualitative CT-scan study. Psychiatry Res 76: 83–87
Yoshioka M, Matsumoto M, Togashi H, Saito H (1996) Effect of conditioned fear stress on dopamine release in the rat prefrontal cortex. Neurosci Lett 209: 201–203
Zwanzger P, Baghai TC, Schule C, Minov C, Padberg F, Moller HJ, Rupprecht R (2001) Tiagabine improves panic and agoraphobia in panic disorder patients. J Clin Psychiatry 62: 656–657
Zwanzger P, Eser D, Aicher S et al (2003) Effects of alprazolam on cholecystokinin-tetrapeptide-induced panic and hypothalamic-pituitary-adrenal-axis activity: a placebo-controlled study. Neuropsychopharmacology 28: 979–984
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2006 Springer Medizin Verlag Heidelberg
About this chapter
Cite this chapter
Bandelow, B., Wedekind, D. (2006). Angst — Neurobiologie. In: Förstl, H., Hautzinger, M., Roth, G. (eds) Neurobiologie psychischer Störungen. Springer, Berlin, Heidelberg. https://doi.org/10.1007/3-540-30887-3_11
Download citation
DOI: https://doi.org/10.1007/3-540-30887-3_11
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-25694-6
Online ISBN: 978-3-540-30887-4
eBook Packages: Medicine (German Language)